PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor.
Locally Advanced/Metastatic Solid Tumors
DRUG: PE0116&PE0105
Occurrence of Drug Limited Toxicities (DLTs), To assess by the occurrence of Drug Limited Toxicities (DLTs), From Time of First dose through DLT observation period, 28 days|Incidence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs)., To assess by the occurrence of Treatment-emergent adverse event (TEAEs) and serious adverse events (SAEs), From the start of treatment until up to 90 days after the last dose of study drug|Number of patients with changes in laboratory parameters from baseline, To assess safety of PE0116\&PE0105, From the start of treatment until up to 30(Â±7) days after the last dose of study drug
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 and PE0105 Injection in Treatment of Patients with Advanced Solid Tumor.